- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 239/48 - Deux atomes d'azote
Détention brevets de la classe C07D 239/48
Brevets de cette classe: 1103
Historique des publications depuis 10 ans
|
92
|
69
|
79
|
55
|
63
|
46
|
53
|
32
|
26
|
5
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Bristol-myers Squibb Company | 4793 |
35 |
| Rigel Pharmaceuticals, Inc. | 517 |
35 |
| Signal Pharmaceuticals, LLC | 177 |
34 |
| Boehringer Ingelheim International GmbH | 4576 |
22 |
| Novartis AG | 10463 |
20 |
| Janssen Sciences Ireland UC | 173 |
19 |
| Merck Patent GmbH | 5741 |
16 |
| Korea Research Institute of Chemical Technology | 1438 |
15 |
| Alexion Pharmaceuticals, Inc. | 644 |
14 |
| Afferent Pharmaceuticals, Inc. | 25 |
13 |
| Dana-Farber Cancer Institute, Inc. | 2641 |
13 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 1005 |
13 |
| Celgene Avilomics Research, Inc. | 31 |
12 |
| Corteva Agriscience LLC | 2652 |
12 |
| Takeda Pharmaceutical Company Limited | 2722 |
11 |
| Portola Pharmaceuticals, Inc. | 86 |
11 |
| FUJIFILM Corporation | 30126 |
10 |
| Roche Palo Alto LLC | 66 |
10 |
| Genentech, Inc. | 4058 |
9 |
| AstraZeneca AB | 2824 |
9 |
| Autres propriétaires | 770 |